Halozyme Therapeutics Inc... (HALO)
58.79
-0.03 (-0.05%)
At close: Apr 17, 2025, 3:59 PM
59.00
0.36%
After-hours: Apr 17, 2025, 07:37 PM EDT
Halozyme Therapeutics Revenue Breakdown
| Period Ending | Sep 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product Revenue | 86.66M | 72.7M | 79.6M | 86.57M | 73.89M | 1.71M | 14.35M | 48M | 20.73M | 25.53M | 32.22M | 60.32M | 30.33M | 57.25M | 32.34M | 33.04M | 385K | 13.74M | 416K | 15.28M | 17.95M | 6.38M | 2.4M | 571K | 3.38M |
| Product Revenue Growth | +19.20% | -8.67% | -8.05% | +17.16% | +4223.52% | -88.09% | -70.09% | +131.59% | -18.83% | -20.75% | -46.58% | +98.85% | -47.02% | +77.04% | -2.12% | +8481.30% | -97.20% | +3203.37% | -97.28% | -14.88% | +181.44% | +165.57% | +320.67% | -83.10% | n/a |
| Collaborative Agreements Revenue | 48.36M | 16.7M | 28.39M | 15.03M | 35.41M | 60.79M | 61.16M | 61.43M | 46.3M | 22.14M | 25.05M | 30.36M | 21.77M | 32.45M | 9.05M | 6.34M | 8.15M | 22.69M | 29.2M | 5.76M | 30.61M | n/a | n/a | n/a | n/a |
| Collaborative Agreements Revenue Growth | +189.55% | -41.16% | +88.84% | -57.55% | -41.76% | -0.60% | -0.43% | +32.67% | +109.12% | -11.61% | -17.50% | +39.48% | -32.93% | +258.70% | +42.78% | -22.22% | -64.10% | -22.30% | +407.03% | -81.18% | n/a | n/a | n/a | n/a | n/a |
| Royalty Revenue | 155.06M | 120.59M | 122.05M | 114.43M | 111.74M | 99.64M | 105.98M | 99.55M | 85.34M | 69.61M | 58.56M | 45.78M | 36.92M | 32M | 23.93M | 15.85M | 16.82M | 17.23M | 16.61M | 18.11M | 8.39M | n/a | n/a | n/a | n/a |
| Royalty Revenue Growth | +28.58% | -1.20% | +6.66% | +2.41% | +12.14% | -5.98% | +6.46% | +16.65% | +22.61% | +18.85% | +27.93% | +23.98% | +15.40% | +33.71% | +51.02% | -5.80% | -2.37% | +3.74% | -8.27% | +115.82% | n/a | n/a | n/a | n/a | n/a |
| Upfront fees Revenue | 27M | 10.51M | n/a | n/a | n/a | n/a | n/a | n/a | 5M | 25M | 2M | 40M | 16.77M | 30M | n/a | 7.26M | n/a | 13M | n/a | 10M | 30M | n/a | n/a | n/a | n/a |
| Upfront fees Revenue Growth | +156.87% | n/a | n/a | n/a | n/a | n/a | n/a | -100.00% | -80.00% | +1150.00% | -95.00% | +138.52% | -44.10% | n/a | -100.00% | n/a | -100.00% | n/a | -100.00% | -66.67% | n/a | n/a | n/a | n/a | n/a |
| bulk rHuPH20 Revenue | 31.49M | n/a | n/a | 37M | 27.13M | 22.07M | 21.32M | 19.26M | 25.06M | 16.45M | 18.86M | 24.06M | n/a | 26.71M | 3.85M | 3.91M | 3.77M | 17.14M | 24.59M | 1.47M | 5.08M | n/a | n/a | n/a | n/a |
| bulk rHuPH20 Revenue Growth | n/a | n/a | n/a | +36.37% | +22.95% | +3.51% | +10.70% | -23.14% | +52.34% | -12.80% | -21.61% | n/a | n/a | +593.82% | -1.48% | +3.74% | -78.02% | -30.31% | +1572.99% | -71.07% | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 |
|---|---|---|---|---|---|---|---|
| Switzerland Revenue | 109.89M | 119.14M | 93.07M | 57.14M | 42.79M | 35.2M | 18.9M |
| Switzerland Revenue Growth | -7.76% | +28.01% | +62.89% | +33.52% | +21.57% | +86.24% | n/a |
| United States Revenue | 40.48M | 196.27M | 52.29M | 77.15M | 31.4M | 19M | 22.7M |
| United States Revenue Growth | -79.38% | +275.34% | -32.22% | +145.72% | +65.25% | -16.30% | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 42.25M | 41.24M | 35.71M | 35.13M | 37.61M | 35.27M | 38.95M | 37.36M | 37.75M | 34.47M | 57.48M | 13.83M | 13.77M | 13.17M | 12.32M | 11.06M | 10.43M | 11.7M | 10.97M | 12.63M | 23.93M | 17.98M | 17.34M | 18.01M | 18.03M | 14.86M | 14.35M | 13.56M | 14.77M | 13.33M | 13.1M | 12.62M | 12.23M | 11.6M | 11.22M | 10.81M | 10.59M | 10.23M | 9.81M | 9.4M |
| Selling, General, and Administrative Revenue Growth | +2.44% | +15.49% | +1.64% | -6.58% | +6.63% | -9.45% | +4.26% | -1.04% | +9.52% | -40.03% | +315.47% | +0.44% | +4.59% | +6.88% | +11.41% | +6.06% | -10.90% | +6.62% | -13.12% | -47.21% | +33.09% | +3.70% | -3.71% | -0.14% | +21.31% | +3.56% | +5.88% | -8.23% | +10.82% | +1.74% | +3.85% | +3.17% | +5.41% | +3.37% | +3.84% | +2.05% | +3.55% | +4.20% | +4.42% | n/a |
| Research and Development Revenue | 20.44M | 18.46M | 21.04M | 19.11M | 21.34M | 17.32M | 19.73M | 17.98M | 22.57M | 16.7M | 15.48M | 11.85M | 10.11M | 8.49M | 8.07M | 9.01M | 7.38M | 7.75M | 8.95M | 10.16M | 45.11M | 30.45M | 33.91M | 31.33M | 36.65M | 35.54M | 40.09M | 37.98M | 41.38M | 33.99M | 38.34M | 36.94M | 41.35M | 33.86M | 35.53M | 40.1M | 27.75M | 27.61M | 21.2M | 16.68M |
| Research and Development Revenue Growth | +10.74% | -12.26% | +10.08% | -10.43% | +23.18% | -12.20% | +9.72% | -20.33% | +35.09% | +7.89% | +30.63% | +17.26% | +19.11% | +5.17% | -10.43% | +22.07% | -4.74% | -13.45% | -11.88% | -77.48% | +48.12% | -10.19% | +8.24% | -14.52% | +3.12% | -11.34% | +5.56% | -8.22% | +21.72% | -11.34% | +3.80% | -10.67% | +22.11% | -4.69% | -11.40% | +44.53% | +0.49% | +30.27% | +27.04% | n/a |